First Line Treatment Choice for Chronic Myelogenous Leukemia: Modeling of Clinical and Economic Factors
Background. Second generation tyrosine kinase inhibitors (nilotinib and dasatinib) have advantages over imatinib in frequency and rate of cytogenetic and molecular responses obtaining in chronic myelogenous leukemia (CML) treatment. At the same time, they produced more severe adverse effects and are...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Russo |
| Vydáno: |
Practical Medicine Publishing House
2015-01-01
|
| Edice: | Клиническая онкогематология |
| Témata: | |
| On-line přístup: | https://bloodjournal.ru/index.php/coh/article/view/528 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|